2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
06/20/17Insys Therapeutics Hires Four Key Pharmaceutical Industry Veterans for Leadership Positions
PHOENIX, June 20, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced the addition of four pharmaceutical industry veterans to its management team. Joining Insys are: Brian Jennings, Vice President of Sales Dr. Dean Mariano, Senior Director, Clinical Development/Medical Affairs; Ariyapadi (Krishna) Krishnaraj, Vice President of Marketing and Managed Care; and, Scott Warlick, General Manager, Manufacturing “These key hire... 
Printer Friendly Version
06/05/17Insys Therapeutics, Inc. Releases Statement on Its Ongoing Mission
PHOENIX, June 05, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) issued a response to the recent media reports that highlight concerns with the Company’s past commercial practices and former employees. Insys reiterates its commitment to: maintaining the highest ethical standards and compliance around all its activities and business practices and complying with governing laws and regulations; providing innovative solutions related to patient c... 
Printer Friendly Version
05/31/17Insys Therapeutics, Inc. to Present at June Conferences
PHOENIX, May 31, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Saeed Motahari, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the following healthcare conferences in June: Conference:       Jefferies 2017 Global Healthcare Conference Date:       Thursday, June 8, 2017 Time:       1... 
Printer Friendly Version
05/24/17Insys Therapeutics, Inc. Announces FDA Final Product Label for Syndros
Launch Planned for August 2017 PHOENIX, May 24, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the final product label for Syndros™ (dronabinol) oral solution, CII, a liquid formulation of the pharmaceutical cannabinoid, dronabinol.  Syndros is approved for use in treating anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (“AIDS”) ... 
Printer Friendly Version
05/16/17Insys Therapeutics Announces Chief Financial Officer Transition
PHOENIX, May 16, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that Darryl S. Baker, the Company's Chief Financial Officer (“CFO”), will transition from the role of CFO when a successor is hired. Insys has engaged an executive search firm to support the recruitment of a new CFO. Mr. Baker will continue to work closely with the management team, including the new CFO, to facilitate a smooth and successful transition of his responsib... 
Printer Friendly Version
05/09/17Insys Therapeutics Reports First Quarter 2017 Results
PHOENIX , May 09, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced financial results for the three-month period ended March 31, 2017 . Highlights of and subsequent to the first quarter of 2017 include: Net revenue totaled $36.0 million , compared to $60.4 million for the first quarter of 2016;   Net loss of $6.5 million , or $(0.09) per basic and diluted share, compared to net income of $2.3 ... 
Printer Friendly Version
05/04/17Insys Therapeutics, Inc. Appoints Rohit Vishnoi to Board of Directors
PHOENIX, Ariz., May 04, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") announced that Rohit Vishnoi, a seasoned healthcare executive, has been appointed to the Company’s Board of Directors, effective as of May 2, 2017.  Mr. Vishnoi has also been appointed to the Company’s Science and Research and Development Committee and Nominating and Corporate Governance Committee. “Rohit Vishnoi’s many assets include a proven track record of balancing strategy... 
Printer Friendly Version
04/25/17Insys Therapeutics to Report First Quarter 2017 Results on May 9, 2017
PHOENIX, April 25, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its first quarter 2017 financial results on Tuesday, May 9, 2017, before the U.S. financial markets open. Following the release of the financial results, Saeed Motahari, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Daylight Time. Interested parties may... 
Printer Friendly Version
04/24/17Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs
PHOENIX, April 24, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") announced that effective today, Dr. Steven James will join the Company as Vice President of Medical Affairs. “Dr. James joins Insys with extensive research and development credentials and a proven record of accomplishments.  We believe he will play a critical role in achieving our mission of improving patients’ care by leveraging our proprietary sublingual spray platform and strong ... 
Printer Friendly Version
04/03/17Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results
PHOENIX, April 03, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced financial results for the three- and twelve-month periods ended December 31, 2016. Highlights of and subsequent to the fourth quarter of 2016 include: Total net revenue decreased to $54.9 million, compared to $93.9 million for the fourth quarter of 2015;   Net loss was $3.7 million, or $(0.05) per basic and diluted share, compared to net income of $18.1 million, ... 
Printer Friendly Version
03/27/17Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017
PHOENIX, March 27, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief Executive Officer (“CEO”) and be appointed to the Company’s Board of Directors. “We are excited that Saeed, a 20-year veteran of the life sciences industry, has chosen to bring his immense depth of sales and marketing, managed care, and commercial operations experience to In... 
Printer Friendly Version
03/23/17DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug
PHOENIX, March 23, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act.  On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros. Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical O... 
Printer Friendly Version
03/15/17Insys Therapeutics Announces Delay in the Release of its Fourth Quarter and Full Year 2016 Results
-- Fourth Quarter 2016 Net Sales Estimated at $54 million -- PHOENIX, March 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that the Company will delay the release of its financial results for the fourth quarter and full year 2016.  The Audit Committee of the Company’s Board of Directors has been conducting an independent review of the Company’s processes related to estimation of, and increases to, certain sales allowances recorde... 
Printer Friendly Version
03/02/17Insys Therapeutics to Report Fourth Quarter and Full Year 2016 Results
PHOENIX, March 02, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its financial results for the fourth quarter and full year 2016 on Thursday, March 16, 2017, before the U.S. financial markets open. Following the release of the financial results, Dr. Santosh Vetticaden, Interim CEO, and Chief Medical Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Da... 
Printer Friendly Version
02/15/17Insys Therapeutics Announces Use of Cannabidiol Oral Solution for Compassionate Use Studies in Patients Completing Long-Term Safety Study
CHANDLER, Ariz., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that the Company is providing for the use of Cannabidiol Oral Solution at doses up to 40 mg/kg/day in compassionate use studies in subjects with refractory pediatric epilepsy following completion of 48 weeks of treatment in the ongoing long-term safety study.  The long-term safety study permitted subjects who had completed the initial safety and pharmacokinetic (... 
Printer Friendly Version
02/14/17Insys Therapeutics, Inc. to Present at 2017 RBC Capital Markets Global Healthcare Conference
PHOENIX, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Interim Chief Executive Officer, and Chief Medical Officer, and Darryl Baker, Chief Financial Officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference as follows: Date:   Thursday, February 23, 2017 Time:   1:35 p.m. Eastern Standard Time Location:   The New ... 
Printer Friendly Version
01/09/17Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board
PHOENIX, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that Dr. John N. Kapoor, its Founder, President and Chief Executive Officer (“CEO”) and Chairman of the Company’s Board of Directors (“Board”) will retire as President and CEO and Chairman effective January 9, 2017.  Dr. Kapoor will remain a member of the Board and will Chair the newly formed Science and Research and Development Committee of the Board.  In connection ... 
Printer Friendly Version
01/04/17Insys Therapeutics, Inc. to Present at J.P. Morgan 35th Annual Healthcare Conference
PHOENIX, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, and Darryl Baker, Chief Financial Officer, will present at the J.P. Morgan 35th Annual Healthcare Conference as follows: Date:   Monday, January 9, 2017   Time:   4:00 p.m. Pacific Standard Time   Location:   We... 
Printer Friendly Version